Opinion: Biden promised a ‘war on cancer’ — but declared war on the cure instead
Ending cancer is an achievable goal, but new Biden administration policies are standing in the way, says PhRMA’s CEO and president.
When then-Vice President Biden launched the Cancer Moonshot in 2016, there was reason to be optimistic. Decades of rigorous science had transformed many cancers from a death sentence to a manageable chronic disease. New treatment advances — including gene and cell therapies and immunotherapies — were showing stunning results. With support from the biopharmaceutical industry and the help of smart government policies, ending cancer was, and is, an achievable goal.
Unfortunately, while the president promised a war on cancer, he declared a war on the cure instead. As the head of PhRMA, an association representing America’s leading biopharmaceutical research companies, I work with my team to closely follow the policy debate and the impact on innovation. While they may have been well-intended, the Biden administration has adopted a series of policies that attack critical steps needed to bring new treatments out of the lab and to the patients who need them.
What's Your Reaction?
